Order Article Reprints

de la Fuente A, Santisteban M, Lupón J, Aramendía JM, Díaz A, Santaballa A, Hernándiz A, Sepúlveda P, Cediel G, López B, et al. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. Cancers. 2022; 14(12):2941. https://doi.org/10.3390/cancers14122941

de la Fuente, Ana, Marta Santisteban, Josep Lupón, José Manuel Aramendía, Agnes Díaz, Ana Santaballa, Amparo Hernándiz, Pilar Sepúlveda, Germán Cediel, Begoña López, and et al. 2022. "A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy" Cancers 14, no. 12: 2941. https://doi.org/10.3390/cancers14122941

de la Fuente, A., Santisteban, M., Lupón, J., Aramendía, J. M., Díaz, A., Santaballa, A., Hernándiz, A., Sepúlveda, P., Cediel, G., López, B., Picazo, J. M. L., Mazo, M. M., Rábago, G., Gavira, J. J., García-Bolao, I., Díez, J., González, A., Bayés-Genís, A., & Ravassa, S. (2022). A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. Cancers, 14(12), 2941. https://doi.org/10.3390/cancers14122941